Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured...
Vaccine
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025...
Vaxart Announces Withdrawal of Reverse Stock Split Proposal
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage...
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense,...
nuBioAge’s Clinical Longevity Summit Gathers World-Leading Physicians in West Palm Beach to Deliver the First Comprehensive Roadmap for Post-COVID Treatment
WEST PALM BEACH, Fla., Sept. 18, 2025 /PRNewswire/ -- On September 12–13, 2025, the Hilton West Palm Beach hosted the Clinical...
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing
The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a...
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder
Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a potential first-in-class treatment for...
David Banach of Woodbridge, CT Calls for Stronger Community Action on Infection Prevention
Physician and educator emphasizes the role of individuals in reducing risks and protecting public health WOODBRIDGE, CT / ACCESS Newswire...
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational...
Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
- Efficacy and safety results from successful NAVIGATE Phase 2b trial of CD388 for prevention of influenza illness featured in...
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1) Planning adaptive Phase...
Improving Maternal Care Remains Critical in U.S.
Patient Transitions, Communication and Hand-Off Issues are Among the Leading Causes of Safety Incidents in Maternal Care WILLOW GROVE, Pa.,...
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groupsClinical...
RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
This release is being retransmitted for extra exposure to downstream sites. SHELTON, CT / ACCESS Newswire / September 11, 2025...
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope®...
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal...
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in...
Pharma Executives Redefine IT Priorities: Five Stats Signal Urgent Tech Shift
Black Book Research Q2-Q3 proprietary surveys reveal digital health, cybersecurity, and data platforms as the foundation of pharma's future competitiveness...
West African Leaders Commit to Advance Lassa Fever Vaccine for the Region
In an historic moment for regional solidarity and leadership, West African Ministers of Health pledge their joint commitment to advance...
NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage...